A new publication dated September 1, 2026 presents a post hoc analysis titled "Liver Fat Changes in Patients With Type 2 Diabetes by Presence of Genetic Hepatic Steatosis: A Post Hoc Analysis of SURPASS-3 MRI." The article appears in Liver International, the official journal of the International Association for the Study of the Liver.
This publication is a post hoc analysis of data from the SURPASS-3 MRI study, which involved patients with type 2 diabetes. The title indicates the analysis examines liver fat changes stratified by the presence of genetic hepatic steatosis. No results, conclusions, or efficacy findings from this analysis have been provided in the available event data.
Insulin degludec is an approved basal insulin used in the management of diabetes. This news item reports only the existence and bibliographic details of the publication as listed, including its title, journal, and publication date. No additional data regarding study outcomes, patient numbers, or comparative findings accompany this entry.
Readers interested in the broader context of insulin degludec research and its regulatory status can consult the compound overview for further information.